Literature DB >> 33603657

Detection Gap of Right-Asymmetric Neuronal Degeneration by CERAD Test Battery in Alzheimer's Disease.

Annika Kreuzer1, Julia Sauerbeck1, Maximilian Scheifele1, Anna Stockbauer1, Sonja Schönecker2, Catharina Prix2, Elisabeth Wlasich2, Sandra V Loosli2, Philipp M Kazmierczak3, Marcus Unterrainer1,3, Cihan Catak4, Daniel Janowitz4, Oliver Pogarell5, Carla Palleis2,6, Robert Perneczky5,6,7,8, Nathalie L Albert1, Peter Bartenstein1,7, Adrian Danek2, Katharina Buerger4,6, Johannes Levin2,6, Andreas Zwergal2, Axel Rominger1,7,9, Matthias Brendel1,7, Leonie Beyer1.   

Abstract

Objectives: Asymmetric disease characteristics on neuroimaging are common in structural and functional imaging of neurodegenerative diseases, particularly in Alzheimer's disease (AD). However, a standardized clinical evaluation of asymmetric neuronal degeneration and its impact on clinical findings has only sporadically been investigated for F-18-fluorodeoxyglucose positron emission tomography (F-18-FDG-PET). This study aimed to evaluate the impact of lateralized neuronal degeneration on the detection of AD by detailed clinical testing. Furthermore, we compared associations between clinical evaluation and lateralized neuronal degeneration between FDG-PET hypometabolism and hippocampal atrophy. Finally, we investigated if specific subtests show associations with lateralized neuronal degeneration.
Methods: One-hundred and forty-six patients with a clinical diagnosis of AD (age 71 ± 8) were investigated by FDG-PET and the "Consortium to Establish a Registry for Alzheimer's disease" (CERAD) test battery. For assessment of neuronal degeneration, FDG-PET hypometabolism in brain regions typically affected in AD were graded by visual (3D-surface projections) and semiquantitative analysis. Asymmetry of the hippocampus (left-right) in magnetic resonance tomography (MRI) was rated visually by the Scheltens scale. Measures of asymmetry were calculated to quantify lateralized neuronal degeneration and asymmetry scores were subsequently correlated with CERAD.
Results: Asymmetry with left-dominant neuronal degeneration to FDG-PET was an independent predictor of cognitive impairment (visual: β = -0.288, p < 0.001; semiquantitative: β = -0.451, p < 0.001) when controlled for age, gender, years of education and total burden of neuronal degeneration, whereas hippocampal asymmetry to MRI was not (β = -0.034; p = 0.731). Direct comparison of CERAD-PET associations in cases with right- and left-lateralized neuronal degeneration estimated a detection gap of 2.7 years for right-lateralized cases. Left-hemispheric neuronal degeneration was significantly associated with the total CERAD score and multiple subscores, whereas only MMSE (semiquantitative: β = 0.429, p < 0.001) and constructional praxis (semiquantitative: β = 0.292, p = 0.008) showed significant associations with right-hemispheric neuronal degeneration. Conclusions: Asymmetry of deteriorated cerebral glucose metabolism has a significant impact on the coupling between neuronal degeneration and cognitive function. Right dominant neuronal degeneration shows a delayed detection by global CERAD testing and requires evaluation of specific subdomains of cognitive testing.
Copyright © 2021 Kreuzer, Sauerbeck, Scheifele, Stockbauer, Schönecker, Prix, Wlasich, Loosli, Kazmierczak, Unterrainer, Catak, Janowitz, Pogarell, Palleis, Perneczky, Albert, Bartenstein, Danek, Buerger, Levin, Zwergal, Rominger, Brendel and Beyer.

Entities:  

Keywords:  Alzheimer’s disease; FDG-PET; asymmetry; cognitive performance; hippocampal atrophy

Year:  2021        PMID: 33603657      PMCID: PMC7884314          DOI: 10.3389/fnagi.2021.611595

Source DB:  PubMed          Journal:  Front Aging Neurosci        ISSN: 1663-4365            Impact factor:   5.750


  42 in total

1.  Caregiver burden in Alzheimer's disease patients in Spain.

Authors:  Luz María Peña-Longobardo; Juan Oliva-Moreno
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Predominant left hemisphere metabolic dysfunction in dementia.

Authors:  D A Loewenstein; W W Barker; J Y Chang; A Apicella; F Yoshii; P Kothari; B Levin; R Duara
Journal:  Arch Neurol       Date:  1989-02

3.  Prevalence and incidence of dementia among 75-80-year-old community-dwelling elderly in different districts of Antwerp, Belgium: the Antwerp Cognition (ANCOG) Study.

Authors:  P P De Deyn; J Goeman; A Vervaet; B Dourcy-Belle-Rose; D Van Dam; E Geerts
Journal:  Clin Neurol Neurosurg       Date:  2011-08-20       Impact factor: 1.876

4.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

Review 5.  Gray matter asymmetries in aging and neurodegeneration: A review and meta-analysis.

Authors:  Lora Minkova; Annegret Habich; Jessica Peter; Christoph P Kaller; Simon B Eickhoff; Stefan Klöppel
Journal:  Hum Brain Mapp       Date:  2017-08-30       Impact factor: 5.038

6.  Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease.

Authors:  J V Haxby; R Duara; C L Grady; N R Cutler; S I Rapoport
Journal:  J Cereb Blood Flow Metab       Date:  1985-06       Impact factor: 6.200

7.  European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus.

Authors:  F Nobili; J Arbizu; F Bouwman; A Drzezga; F Agosta; P Nestor; Z Walker; M Boccardi
Journal:  Eur J Neurol       Date:  2018-07-20       Impact factor: 6.089

8.  Neural correlates of dementia: regional brain metabolism (FDG-PET) and the CERAD neuropsychological battery.

Authors:  K A Welsh; J M Hoffman; N L Earl; M W Hanson
Journal:  Arch Clin Neuropsychol       Date:  1994-10       Impact factor: 2.813

9.  Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer's disease: Meta-analyses of MRI studies.

Authors:  Feng Shi; Bing Liu; Yuan Zhou; Chunshui Yu; Tianzi Jiang
Journal:  Hippocampus       Date:  2009-11       Impact factor: 3.899

Review 10.  A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis.

Authors:  Daniela Perani; Perani Daniela; Orazio Schillaci; Schillaci Orazio; Alessandro Padovani; Padovani Alessandro; Flavio Mariano Nobili; Nobili Flavio Mariano; Leonardo Iaccarino; Iaccarino Leonardo; Pasquale Anthony Della Rosa; Della Rosa Pasquale Anthony; Giovanni Frisoni; Frisoni Giovanni; Carlo Caltagirone; Caltagirone Carlo
Journal:  Biomed Res Int       Date:  2014-03-19       Impact factor: 3.411

View more
  1 in total

1.  Dual-Phase β-Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome.

Authors:  Julia Schmitt; Carla Palleis; Julia Sauerbeck; Marcus Unterrainer; Stefanie Harris; Catharina Prix; Endy Weidinger; Sabrina Katzdobler; Olivia Wagemann; Adrian Danek; Leonie Beyer; Boris-Stephan Rauchmann; Axel Rominger; Mikael Simons; Peter Bartenstein; Robert Perneczky; Christian Haass; Johannes Levin; Günter U Höglinger; Matthias Brendel
Journal:  Front Aging Neurosci       Date:  2021-05-13       Impact factor: 5.750

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.